Kathleen Jentsch‐Ullrich

Author

Also Known As

Dietrich Kämpfe, K JENTSCHULLRICH, K Jentsch-Ullrich, K. Jentsch-Ullrich, K. Jentsch‐Ullrich, K., Jentsch-Ullrich, K. Jentsch-Ullrich, KATHLEEN JENTSCH‐ULLRICH, Kathleen Jentsch-Ullrich, Kathleen Jentsch‐Ullrich

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

University Hospital Magdeburg Otto-von-Guericke University Magdeburg Klinikum Magdeburg Praxis für Hämatologie und Onkologie Technical University of Munich

About

Kathleen Jentsch‐Ullrich is an author at University Hospital Magdeburg specializing in medicine, hematology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	14	709
2	Health Sciences	4	4	137
3	Cell Biology	3	3	64
4	Cellular Therapies	3	3	127
5	Blood Transplantation	1	1	21

Kathleen Jentsch‐Ullrich

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Lymphocyte subsets' reference ranges in an age- and gender-balanced population of 100 healthy adults—A monocentric German study Kathleen Jentsch‐Ullrich, Michael Koenigsmann, Martin Mohren, Clinical Immunology Lymphocyte DevelopmentClinical PopulationImmunodeficienciesImmunologyHematology	2005	186
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial Judith Trotman, Sally F. Barrington, David Belada, The Lancet Oncology Lymphoid NeoplasiaEnd-of-induction Pet ResponseMedicinePrognostic ValueFollicular Lymphoma	2018	152
Thromboembolic complications after splenectomy for hematologic diseases Martin Mohren, Ilka Markmann, Ulrike Dworschak, American Journal of Hematology	2004	113
Increased risk of thromboembolism in patients with malignant lymphoma: a single-centre analysis Martin Mohren, Ilka Markmann, Kathleen Jentsch‐Ullrich, British Journal of Cancer	2005	77
Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation Stefanie Zschäbitz, Felix Lasitschka, Boris Hadaschik, European Journal of Cancer Cell TherapyMedicineStem Cell TransplantationImmunologyImmune Checkpoint Inhibitor	2017	76
Use of capillary blood count parameters in adults Enrico Schalk, M.U. Heim, Michael Koenigsmann, Vox Sanguinis	2007	69
Increased risk of venous thromboembolism in patients with acute leukaemia Martin Mohren, Ilka Markmann, Kathleen Jentsch‐Ullrich, British Journal of Cancer	2006	65
Effect of Atrial Fibrillation on Hematopoietic Progenitor Cells Andreas Goette, Kathleen Jentsch‐Ullrich, Uwe Lendeckel, Circulation	2003	59
A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma – long-term results of a multicenter observation study Oliver Weigert, Eckhart Weidmann, Rudolf Mueck, Leukemia & lymphoma/Leukemia and lymphoma	2009	58
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study Anna Maria Fink, Jasmin Bahlo, Sandra Robrecht, The Lancet Haematology Hematological MalignancyLymphoid NeoplasiaFirst-line TherapyOncologyImmunology	2017	54

Page 1